Vaxil Bio Ltd.
VXLLF
$0.13
$0.122,021.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 211.64% | 66.08% | 14.74% | -71.03% | -80.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.40% | 5.53% | -26.66% | -72.65% | -82.06% |
| Operating Income | -89.40% | -5.53% | 26.66% | 72.65% | 82.06% |
| Income Before Tax | 1.46% | 5.89% | 33.60% | 73.01% | 82.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.46% | 5.89% | 33.60% | 73.01% | 82.06% |
| Earnings from Discontinued Operations | 184.31% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.15% | 2.23% | 30.90% | 71.49% | 80.85% |
| EBIT | -89.40% | -5.53% | 26.66% | 72.65% | 82.06% |
| EBITDA | -- | -- | -- | 106.87% | 99.76% |
| EPS Basic | 13.27% | 2.17% | 30.81% | 71.46% | 80.86% |
| Normalized Basic EPS | 1.16% | 5.97% | 33.64% | 74.42% | 82.10% |
| EPS Diluted | 13.27% | 2.17% | 30.81% | 71.46% | 80.86% |
| Normalized Diluted EPS | 1.16% | 5.97% | 33.64% | 74.42% | 82.10% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |